Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin
Aims/hypothesis We aimed to compare diabetic retinopathy outcomes in people with type 1 diabetes following introduction of continuous subcutaneous insulin infusion (CSII) therapy with outcomes in people receiving continuing therapy with multiple daily insulin injections (MDI). Methods This is a retr...
Saved in:
| Published in: | Diabetologia Vol. 64; no. 8; pp. 1725 - 1736 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.08.2021
Springer Nature B.V |
| Subjects: | |
| ISSN: | 0012-186X, 1432-0428, 1432-0428 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aims/hypothesis
We aimed to compare diabetic retinopathy outcomes in people with type 1 diabetes following introduction of continuous subcutaneous insulin infusion (CSII) therapy with outcomes in people receiving continuing therapy with multiple daily insulin injections (MDI).
Methods
This is a retrospective cohort study using the Scottish Care Information – Diabetes database for retinal screening outcomes and HbA
1c
changes in 204 adults commenced on CSII therapy between 2013 and 2016, and 211 adults eligible for CSII during the same period but who continued on MDI therapy. Diabetic retinopathy progression (time to minimum one-grade worsening in diabetic retinopathy from baseline grading) was plotted for CSII and MDI cohorts using Kaplan–Meier curves, and outcomes were compared using multivariate Cox regression analysis adjusting for age, sex, baseline HbA
1c
, blood pressure, cholesterol, smoking status and socioeconomic quintile. Impact of baseline HbA
1c
and change in HbA
1c
on diabetic retinopathy progression was assessed within CSII and MDI cohorts.
Results
CSII participants were significantly younger, were from less socially deprived areas, and had lower HbA
1c
and higher diastolic BP at baseline. There was a larger reduction in HbA
1c
at 1 year in those on CSII vs MDI (−6 mmol/mol [−0.6%] vs −2 mmol/mol [−0.2%],
p
< 0.01). Diabetic retinopathy progression occurred in a smaller proportion of adults following commencement of CSII vs continued MDI therapy over mean 2.3 year follow-up (26.5% vs 18.6%,
p
= 0.0097). High baseline HbA
1c
(75 mmol/mol [9%]) was associated with diabetic retinopathy progression in the MDI group (
p
= 0.0049) but not the CSII group (
p
= 0.93). Change in HbA
1c
at follow-up, irrespective of baseline glycaemic status, did not significantly affect diabetic retinopathy progression in either group.
Conclusions/interpretation
CSII was associated with reduced diabetic retinopathy progression compared with continued MDI therapy, and may be protective against diabetic retinopathy progression for those with high baseline HbA
1c
. Progression of diabetic retinopathy over 3 years was not associated with a change in HbA
1c
.
Graphical abstract |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 0012-186X 1432-0428 1432-0428 |
| DOI: | 10.1007/s00125-021-05456-w |